EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
By Denny Jacob
EyePoint Pharmaceuticals shares slide 32% after disclosing that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
Shares were trading around $13.46 after resuming trading at 7:30 a.m. ET following a halt at 6:55 a.m. ET. The stock is down 15% on the year so far.
Non-proliferative diabetic retinopathy is an early stage of diabetic retinopathy, a leading cause of blindness in working age adults, in which symptoms may be mild or nonexistent.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 06, 2024 08:05 ET (12:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing